Avid Bioservices, a CDMO specializing in biologic drugs, is going private in a $1.1 billion M&A deal with private equity firms GHO Capital Partners and Ampersand Capital Partners. The deal values Avid at $12.50 per share, a premium to its stock price. Avid was formerly a subsidiary of Peregrine Pharmaceuticals, focusing on CDMO work since 2018. For fiscal 2024, Avid reported a revenue decline to $139.9 million, with top three customers contributing 55% of revenue. Avid’s CEO sees the acquisition as an opportunity for growth. The deal is expected to close in the first quarter of 2025 pending shareholder approval.
Source link
Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition
